Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer

BackgroundNew therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce durable responses in bladder cancer while maximizing T cells at the tumor sit...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang‘, Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams, Cheryl Cox, Amy M. Hall, Matthew S. Beatty, Michael Poch, Katarzyna A. Rejniak, Shari Pilon-Thomas
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-10-01
Serija:	Frontiers in Immunology
Teme:	tumor infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) non-muscle invasive bladder cancer (NMIBC) neoadjuvant gemcitabine lymphodepletion
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1275375/full
Oznake:	Označite Brez oznak, prvi označite!